LEUKOTRIENE RECEPTOR ANTAGONISTS IN DIFFERENT PHENOTYPES OF BRONCHIAL ASTHMA
https://doi.org/10.18093/0869-0189-2014-0-2-110-115
Abstract
Cysteinyl leukotrienes which are products of lipoxygenase pathway of arachidonic acid metabolism play an important role in all phenotypes of bronchial asthma (BA). They are involved in immune and non-immune stimulation of different cells and inflammatory mechanisms in BA. Leukotrienes cause bronchoconstriction, increase vascular permeability and bronchial mucosa oedema, stimulate mucus secretion. Knowledge of
leukotriene as inflammation mediators has allowed development leukotriene receptor antagonists and their implementation in clinical practice. Antiinflammatory properties of leukotriene receptor antagonists facilitate achievement asthma control while using both as monotherapy in mild asthma and in combinations with other antiasthmatic drugs in more severe disease. Currently, ongoing research of asthma phenotypes could define
certain phenotypes with more important role of leukotrienes.
leukotriene as inflammation mediators has allowed development leukotriene receptor antagonists and their implementation in clinical practice. Antiinflammatory properties of leukotriene receptor antagonists facilitate achievement asthma control while using both as monotherapy in mild asthma and in combinations with other antiasthmatic drugs in more severe disease. Currently, ongoing research of asthma phenotypes could define
certain phenotypes with more important role of leukotrienes.
About the Author
N. P. Knyazheskaya
ГБОУ ВПО "Российский государственный медицинский университет им. Н.И.Пирогова" Минздрава России: 117997, Москва, ул. Островитянова, 1
Russian Federation
Russian Federation
References
1. Global Initiative for Asthma. Workshop Report, 2011. http://www.ginasthma.com/download.asp?intId=217
2. Holgate S., Dahlen S-E., eds. SRS-A to Leukotrienes: The Dawning of a New Treatment. Oxford, UK: Blackwell Science Ltd; 1997.
3. O'Byrne P.M. Leukotrienes in the pathogenesis of asthma. Chest. 1997; 111: 27S–34S.
4. Feldberg W., Kellaway C.H. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J. Physiol. (Lond.). 1938; 94 (2): 187–226.
5. Вылегжанина Т.Г. Взаимосвязь аллергического ринита и бронхиальной астмы. Consilium Medicum. 2001; 3 (12): 579–581. / Vylegzhanina T.G. A relationship between aller- gic rhinitis and bronchial asthma. Consilium Medicum. 2001; 3 (12): 579–581 (in Russian).
6. Shore S. Obesity and asthma: lessons from animal models. J. Appl. Physiol. 2007; 102: 516–528.
7. Hernandez-Alvidrez E., Alba-Reyes G., Munoz-Cedillo B.C. et al. Passive smoking induces leukotriene production in children: influence of asthma. J. Asthma. 2013; 50 (4): 347–353.
8. Hedman J., Kaprio J., Poussa T. et al. Prevalence of asthma, aspirin intolerance, nacal polyposis and chronic obstructive pulmonary disease in population-based study. Int. J. Epidemiol. 1999; 28: 717–722.
9. Szczeklik A., Stevenson D.D. Aspirin-induced asthma: advances in pathogenesis and management. J. Clin. Immunol. 1999; 104: 5–13.
10. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur. Respir. J. 1990; 3: 588–593.
11. McMains K.C., Kountakis S.E. Medical and surgical considerations in patients with Samter's triad. OceanSide Publications, Inc. Am. J. Rhinol. 2006; 20 (6): 573–576.
12. Paganin F., Poubeau P., Yvin J.L. Arvin-Berod The effectiveness of leukotriene antagonists in the treatment o aspirinintolerant asthmatic patient. Presse Med. 2003; 32 (21): 978–984.
13. Лопатин А.С., Гущин И.С., Емельянов А.В.и др. Клинические рекомендации по диагностике и лечению аллергического ринита. Consilium Medicum. 2001; Прил.: 33–44. / Lopatin A.S., Gushchin I.S., Emelyanov A.V. et al. Clinical guidelines on diagnosis and treatment of allergic rhinitis. Consilium Medicum. 2001; Pril.: 33–44 (in Russian).
14. Bjermer L., Anderson S.D. Bronchial hyperrcspoiisiveness in athletes: mechanisms for development. In: Carlsen K.H., Delgado L., Del Giacco S., eds. Diagnosis, Prevention and Treatment of Exercise-Related Asthma, Icspiialoiy and Allergic Disordes in Sports. Eur. Respir. Monograph. 2005; 33: 19–34.
15. Duranti R. Exercise-induced bronchoconstriction: protocols. Study with the experts. Interactive Course on Basic principles of clinical exercise testing. Rome, Italy, March 2–4, 2006. ERS School Courses. 2006.
16. Hallstrand T.S. Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction. J. Pediatr. 2002; 141: 343–349.
17. Астафьева Н.Г. Астма и спорт. Consilium Medicum. 2008; 1:45–50. / Astaf`eva N.G. Astma and sport. Consilium Medicum. 2008; 1: 45–50 (in Russian).
18. Чучалин А.Г. Спорт и бронхиальная астма. Пульмонология и аллергология. 2005; 2: 3–5. / Chuchalin A.G. Sport and bronchial asthma. Pul'monologiya i allergologiya. 2005; 2: 3–5 (in Russian).
19. Larsson K., Ohlsen P., Larsson L. et al. High prevalence of asthma in cross country skiers. Br. Med. J. 1993; 307: 1326–1329.
20. Weiler J.M., Layton Ò., Hunt M. Asthma in United States Olympic athletes who participated in the 1996 Summer Games. J. Allergy Clin. Immunol. 1998; 102: 722–6.
21. Paiange R., Brusasco V., Delgado L., Del Giacco S. Exercise and airway pathology: interactions with immune and allergic responses. In: Carlsen Ê.Í., Delgado L., Del Giacco S., eds. Diagnosis, Prevention and Treatment of Exercise-Related Asthma, Respiratory and Allergic Disordes in Sports. Eur. Respir. Monograph. 2005; 33: 10–18.
22. Chalmers G.W., Macleod K.J., Little S.A. et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002; 57 (3): 226–230.
23. Chaudhuri R., Livingston E., McMahon A.D. et al. Cigarette smoking impairs the therapeutic response to oralcorticosteroids in chronic asthma. Am. J. Respir. Crit. Care Med. 2003; 168 (11): 1308–1311.
24. Tomlinson J.E.M., McMahon A.D., Chaudhuri R. et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005; 60 (4): 282–287.
25. Livingston E., Chaudhuri R., McMahon A.D. et al. Systemic sensitivity to corticosteroids in smokers withasthma. Eur. Respir. J. 2007; 29 (1): 64–71.
26. Price D., Popov T.A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers. J. Allergy Clin. Immunol. 2013; 131 (3): 763–771.
27. Beuther D.A., Sutherland E.R. Overweight, obesity, and incidentasthma: a meta-analysis of prospective epidemiologic studies. Am. J. Respir. Crit. Care Med. 2007; 175: 661–666.
28. Price D.B., Swern A., Tozzi C.A. et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61: 737–742.
29. Keith P.K., Koch C., Djandji M. et al.Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can. Respir. J. 2009; 16 (Suppl. A): 17A–31A.
30. Bjermer L. The role of small airway disease in asthma. Curr. Opin. Pulm. Med. 2014; 20 (1): 23–30.
31. Chen X., Wang K., Jiang M., Nong G.M. Leukotriene receptor antagonists for small-airway abnormalities in asthmatics: a systematic review and meta-analysis. J. Asthma 2013; 50 (7): 695–704.
32. Vaquerizo M.J., Casan P., Castillo J. et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003; 58: 211–216.
33. Virchow J.C., Mehta A., Ljungblad L., Mitfessel H. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast. In Chronic Asthma (MONICA) study. Respir. Med. 2010; 104 (5): 644–651.
34. Bisgaard H., Skoner D., Boza M.L. et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr. Pulmonol. 2009; 44 (6): 568–579.
35. Knorr B., Nguyen H.H., Kearns G.L. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. J. Clin. Pharmacol. 2001; 41 (6): 612–619.
36. Wechsler M.E., Pauwels R., Drazen J.M. Leukotriene modifiers and Churg-Strauss syndrome. Adverse effect or response to corticosteroid withdrawal? Drug Saf. 1999; 21: 241–251.
37. Stirling R.G., Chung .KF. Leukotriene antagonists and Churg-Strauss syndrome: the smoking gun. Thorax. 1999; 54: 865–866.
38. Solans R., Bosch J.A., Perez-Bocanegra C. et al. Churg–Strauss syndrome: outcome and long-term follow up of 32 patients. Rheumatology. 2001; 40: 763–771.
Review
For citations:
Knyazheskaya N.P. LEUKOTRIENE RECEPTOR ANTAGONISTS IN DIFFERENT PHENOTYPES OF BRONCHIAL ASTHMA. PULMONOLOGIYA. 2014;(2):110-115. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-2-110-115
Views:
6597
Email this article 